Tivic Health SystemsTIVC
TIVC
About: Tivic Health Systems Inc is a health technology company focused on developing and commercializing non-invasive bioelectronic medicine. The company's platform-based technology activates the body's own healing mechanisms and can be programmed to treat various disease conditions. company's products provide a natural alternative to the standard synthetic chemical methods used by the pharmaceutical industry. ClearUP Sinus Relief, is a first commercial product of the company which is a patented handled device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions.
Employees: 7
0
Funds holding %
of 7,310 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
2.83% less ownership
Funds ownership: 2.83% [Q4 2024] → 0% (-2.83%) [Q1 2025]
78% less funds holding
Funds holding: 9 [Q4 2024] → 2 (-7) [Q1 2025]
100% less capital invested
Capital invested by funds: $90.7K [Q4 2024] → $54 (-$90.6K) [Q1 2025]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for TIVC.
Financial journalist opinion
Neutral
Business Wire
1 week ago
Tivic Health Completes Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced it has completed all study visits in the Optimization Study for its patent pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. Initial findings reinforce the importance of personalization for therapeutic efficacy. Tivic expects to release the study results later this year.
Neutral
Business Wire
1 week ago
Tivic Health Announces 2025 Annual Meeting of Stockholders
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today its Virtual Annual General Meeting of Shareholders will be held on Monday, June 30, 2025 at 1:00 PM, Pacific Time | 4:00 PM Eastern Time. The Company has adopted a virtual format for its Annual Meeting to provide a consistent and convenient experience for all stockholders regardless of their location. In lieu of a live Q&A session, stockholders can submit questio.
Neutral
Seeking Alpha
1 month ago
Tivic Health Systems Inc. (TIVC) Q1 2025 Earnings Call Transcript
Tivic Health Systems Inc. (NASDAQ:TIVC ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Jennifer Ernst – Chief Executive Officer Lisa Wolf – Interim Chief Financial Officer Michael Handley – Chief Operating Officer and President-Tivic Biopharma Division Conference Call Participants Operator Welcome to Tivic Health Systems First Quarter 2025 Financial Results and Operational Update Conference Call. This call has been prerecorded, and the questions you have submitted in advance will be answered following the prepared remarks.
Neutral
Business Wire
1 month ago
Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced financial results for the first quarter ended March 31, 2025 and outlined operational highlights based on its newly expanded clinical pipeline. “This is a defining time for the company. During the quarter we initiated a significant strategic shift, dramatically expanding Tivic's clinical pipeline for restoring immune system health," stated Tivic CEO Jennifer Er.
Neutral
Business Wire
1 month ago
Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food & Drug Administration. Scorpius BioManufacturing, Inc.
Neutral
Business Wire
1 month ago
Tivic Expands VNS Intellectual Property Portfolio
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today it is expanding its non-invasive VNS patent portfolio with the filing of a new patent application with the United States Patent and Trademark Office. Patent No. 63,801,058 entitled “Vagus Nerve Stimulation System” expands the claims and protection around the technology that Tivic is developing and which it expects will redefine state-of-the art in non-invasive vagus.
Neutral
Business Wire
1 month ago
Tivic Health to Report First Quarter 2025 Financial Results on May 15th Via Conference Call and Webcast
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its first quarter results for 2025 via pre-recorded conference call and webcast on Thursday, May 15, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID: 13753498 Webcast Li.
Neutral
Business Wire
2 months ago
Tivic Health Reports White House Briefing and FDA Meetings Secured Positive Interest in Potential Military and Defense Applications of Its Product Candidates
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that it provided briefings to senior leadership at the White House and FDA which garnered significant positive interest in potential military and defense applications for its biologic and bioelectronic product candidates. Both meetings were held in Washington, D.C. on April 17th. The U.S. Government, through agencies including BARDA, NASA, Defense Threats Reduction A.
Neutral
Business Wire
2 months ago
Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod™ for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor 5 (TLR5) immunotherapy program Entolimod™. Neutropenia is a condition characterized b.
Neutral
Business Wire
2 months ago
Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that it has received confirmation from Nasdaq that the Company has regained compliance with the minimum bid requirements of Nasdaq Listing Rule 5550(a)(2). Consequently, Tivic Health's common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol “TIVC.” About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics com.
Charts implemented using Lightweight Charts™